Diabetic kidney disease (DKD) is a common consequence of type 1 diabetes (T1D). It occurs because diabetes damages blood vessels and other cells in the kidneys. It is detected by finding increased protein in the urine or loss of kidney function, and can ultimately lead to kidney failure that needs dialysis or kidney transplantation. One proven way to prevent diabetic kidney disease in T1D patients is by strict blood sugar control through the use of insulin.
Dr. Cherney and his research team is conducting an international clinical trial of a drug called sotagliflozin (SOTA). SOTA reduces the absorption of glucose (also called sugar) from the gut and increases the passing of sugar (and sodium) in the urine. By doing so, it lowers blood sugar. Studies have shown that SOTA and drugs like it may slow progression of diabetic kidney disease in persons with type 2 diabetes. However, the effect of SOTA on kidney function people with type 1 diabetes has not been studied.
The purpose of this study is to find out if SOTA can slow the decline in kidney function in people with T1D and moderate to severe DKD.
For more study information, please contact the study team.
About the author
David Cherney
Dr. Cherney is a Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory. Dr. Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation. His research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic kidney disease and related cardiovascular disease.